India · Delayed Price · Currency is INR Rossari Biotech Earnings Call Transcripts
Fiscal Year 2026
-
Q4 and FY 2026 saw record revenue and EBITDA, with 15% annual growth driven by all segments and strong exports. FY 2027 guidance targets similar or higher growth and 12%-13% EBITDA margins, supported by new capacities, product mix improvements, and cost optimization.
-
Q3 FY26 saw 13% YoY revenue growth, led by strong export performance and broad-based segment gains, though margins were impacted by ongoing investments and EO supply constraints. New capacity ramp-ups and international expansion, especially in Saudi Arabia, are expected to drive future growth.
-
Q2 FY 2026 saw 18% revenue growth, led by strong volumes across all core segments and robust export momentum, despite margin pressures from tariffs and pricing. New capacities and product launches support a positive outlook, with stable EBITDA margin guidance and prudent capital allocation.
-
Q1 FY26 saw 11% YoY revenue growth, led by HPPC and AHN, with EBITDA margin at 12.5%. Capacity expansions and international initiatives are underway, with mid-double-digit growth and margin improvement expected as new facilities ramp up and export headwinds ease.
Fiscal Year 2025
-
Revenue grew 13.6% YoY to INR 2,080 crores in FY 2025, with strong momentum in institutional and B2C verticals and stable core margins. CapEx of INR 192 crores is underway to support future growth, with FY 2026 targeting mid-teens revenue growth and margin improvement.
-
Q3 FY25 saw 10.5% YOY revenue growth to INR 512.7 crore, led by strong exports and improved gross margins, though EBITDA margin declined due to higher costs from expansion and hiring. Capacity additions and export growth are expected to drive future performance, with EO supply a key risk.